Abstract
Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.
Keywords:
Brentuximab Vedotin; CD30; anaplastic large cell lymphoma; cytokine release syndrome; infusion reaction.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Brentuximab Vedotin
-
Cyclophosphamide / therapeutic use
-
Cytokines / metabolism*
-
Doxorubicin / therapeutic use
-
Etoposide / therapeutic use
-
Humans
-
Immunoconjugates / administration & dosage*
-
Immunoconjugates / adverse effects*
-
Lymphoma, Large-Cell, Anaplastic / complications*
-
Lymphoma, Large-Cell, Anaplastic / drug therapy*
-
Lymphoma, Large-Cell, Anaplastic / pathology
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Prednisolone / therapeutic use
-
Remission Induction
-
Syndrome
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Antineoplastic Agents
-
Cytokines
-
Immunoconjugates
-
Vincristine
-
Etoposide
-
Brentuximab Vedotin
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone